A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy

Post-marketing Observational Study of Tasfygo Tablet 35 mg to Evaluate the Safety of Tasfygo in Patients With Unresectable Biliary Tract Cancer With FGFR2 Fusion Gene Positivity Who Progressed After Chemotherapy

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06793709

Enrollment

Registered

2025-01-27

Start date

2025-07-10

Completion date

2032-11-20

Last updated

2026-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biliary Tract Cancer

Keywords

Tasfygo, FGFR2 fusion, Cancer

Brief summary

The primary purpose of this study is to investigate the safety of Tasfygo.

Interventions

OTHERNo Intervention

This is a non-interventional study.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1\. Participants with unresectable biliary tract cancer with FGFR2 fusion gene positivity who are naïve to Tasfygo tablet and progressed after chemotherapy.

Exclusion criteria

Not applicable.

Design outcomes

Primary

Measure	Time frame
Number of Participants With Adverse Drug Reactions	Up to 1 year

Secondary

Measure	Time frame
Percentage of Participants With Best Overall Response (BOR) Based on Physician's Assessment	Up to 1 year

Countries

Japan

Contacts

CONTACTEisai Inquiry Service

eisai-chiken_hotline@hhc.eisai.co.jp

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026